The integration of body functions in humans and other higher organisms is carried out by the nervous system, the immune system, and the endocrine system. The endocrine system is composed of a number of tissues that secrete their products, endocrine hormones, into the circulatory system; from there they are disseminated throughout the body, regulating the function of distant tissues and maintaining homeostasis. In a separate but related system, exocrine tissues secrete their products into ducts and then to the outside of the body or to the intestinal tract. Classically, endocrine hormones are considered to be derived from amino acids, peptides, or sterols and to act at sites distant from their tissue of origin. However, the latter definition has begun to blur as it is found that some secreted substances act at a distance (classical endocrines), close to the cells that secrete them (paracrines), or directly on the cell that secreted them (autocrines). Insulin-like growth factor-I (IGF-I), which behaves as an endocrine, paracrine, and autocrine, provides a prime example of this difficulty.
Hormones are normally present in the plasma and interstitial tissue at concentrations in the range of 10-7M to 10-10M. Because of these very low physiological concentrations, sensitive protein receptors have evolved in target tissues to sense the presence of very weak signals. In addition, systemic feedback mechanisms have evolved to regulate the production of endocrine hormones.
Once a hormone is secreted by an endocrine tissue, it generally binds to a specific plasma protein carrier, with the complex being disseminated to distant tissues. Plasma carrier proteins exist for all classes of endocrine hormones. Carrier proteins for peptide hormones prevent hormone destruction by plasma proteases. Carriers for steroid and thyroid hormones allow these very hydrophobic substances to be present in the plasma at concentrations several hundred-fold greater than their solubility in water would permit. Carriers for small, hydrophilic amino acid-derived hormones prevent their filtration through the renal glomerulus, greatly prolonging their circulating half-life.
Tissues capable of responding to endocrines have 2 properties in common: they posses a receptor having very high affinity for hormone, and the receptor is coupled to a process that regulates metabolism of the target cells. Receptors for most amino acid-derived hormones and all peptide hormones are located on the plasma membrane. Activation of these receptors by hormones (the first messenger) leads to the intracellular production of a second messenger, such as cAMP, which is responsible for initiating the intracellular biological response. Steroid and thyroid hormones are hydrophobic and diffuse from their binding proteins in the plasma, across the plasma membrane to intracellularly localized receptors. The resultant complex of steroid and receptor bind to response elements of nuclear DNA, regulating the production of mRNA for specific proteins.back to the top
With the exception of the thyroid hormone receptor, the receptors for amino acid-derived and peptide hormones are located in the plasma membrane. Receptor structure is varied: some receptors consist of a single polypeptide chain with a domain on either side of the membrane, connected by a membrane-spanning domain. Some receptors are comprised of a single polypeptide chain that is passed back and forth in serpentine fashion across the membrane, giving multiple intracellular, transmembrane, and extracellular domains. Other receptors are composed of multiple polypeptides. For example, the insulin receptor is a disulfide-linked tetramer with the β-subunits spanning the membrane and the α-subunits located on the exterior surface.
Subsequent to hormone binding, a signal is transduced to the interior of the cell, where second messengers and phosphorylated proteins generate appropriate metabolic responses. The main second messengers are cAMP, Ca2+, inositol triphosphate (IP3), and diacylglycerol (DAG). The generation of cAMP occurs via activation of G-protein coupled receptors (GPCRs) whose associated G-proteins activated adenylate cyclase. For more information on GPCRs and G-proteins visit the Signal Transduction page. Adenylate cyclase then converts ATP to cAMP and the subsequent increases in cAMP lead to activation of cAMP-dependent protein kinase (PKA) as shown in the Figure below. GPCRs also couple to G-protein activation of phospholipase C-β (PLCβ). Activated PLCβ hydrolyzes membrane phospholipids (as described below) resulting in increased levels of IP3 and DAG. Downstream signaling proteins are phosphorylated on serine and threonine by PKA and DAG-activated protein kinase C (PKC) leading to alterations in their activities. Additionally, a series of membrane-associated and intracellular tyrosine kinases phosphorylate specific tyrosine residues on target enzymes and other regulatory proteins.
The hormone-binding signal of most, but not all, plasma membrane receptors is transduced to the interior of cells by the binding of receptor-ligand complexes to a series of membrane-localized GDP/GTP binding proteins known as G-proteins. The classic interactions between receptors, G-protein transducer, and membrane-localized adenylate cyclase are illustrated below using the pancreatic hormone glucagon as an example. When G-proteins bind to receptors, GTP exchanges with GDP bound to the α subunit of the G-protein. The Gα-GTP complex binds adenylate cyclase, activating the enzyme. The activation of adenylate cyclase leads to cAMP production in the cytosol and to the activation of PKA, followed by regulatory phosphorylation of numerous enzymes. Stimulatory G-proteins are designated Gs, inhibitory G-proteins are designated Gi. For more information on G-proteins and GPCRs visit the Signal Transduction page.
Representative pathway for the activation of cAMP-dependent protein kinase, PKA. In this example glucagon binds to its' cell-surface receptor, thereby activating the receptor. Activation of the receptor is coupled to the activation of a receptor-coupled G-protein (GTP-binding and hydrolyzing protein) composed of 3 subunits. Upon activation the α-subunit dissociates and binds to and activates adenylate cyclase. Adenylate cyclase then converts ATP to cyclic-AMP (cAMP). The cAMP thus produced then binds to the regulatory subunits of PKA leading to dissociation of the associated catalytic subunits. The catalytic subunits are inactive until dissociated from the regulatory subunits. Once released the catalytic subunits of PKA phosphorylate numerous substrate using ATP as the phosphate donor.
A second class of peptide hormones induces the transduction of two second messengers, DAG and IP3 (diagrammed below for α1-adrenergic stimulation by epinephrine). Hormone binding is followed by interaction with a stimulatory G-protein which is followed in turn by G-protein activation of membrane-localized PLCβ. G-proteins that are coupled to receptor-activation of PLCβ are termed Gq-proteins. PLCβ hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to produce two messengers: IP3, which is soluble in the cytosol, and DAG, which remains in the membrane phase. Cytosolic IP3 binds to sites on the endoplasmic reticulum, opening Ca2+ channels and allowing stored Ca2+ to flood the cytosol. There it activates numerous enzymes, many by activating their calmodulin or calmodulin-like subunits. DAG has two roles: it binds and activates protein kinase C (PKC), and it opens Ca2+ channels in the plasma membrane, reinforcing the effect of IP3. Like PKA, PKC phosphorylates serine and threonine residues of many proteins, thus modulating their catalytic activity.
Pathways involved in the regulation of glycogen phosphorylase by epinephrine. Epinephrine (and norepinephrine) activation of α1-adrenergic receptors (see the Glycogen page for details of the regulatory mechanisms) involves the subsequent activation of the associated Gq-type G-protein followed by activation of phospholipase Cβ, PLCβ. GS-GP kinase is glycogen synthase-glycogen phosphorylase kinase. Often simply referred to as phosphorylase kinase.
Only one receptor class, that for the natriuretic peptides (e.g. atrial natriuretic peptide, ANP: also sometimes called atrial natriuretic factor, ANF), has been shown to be coupled to the production of intracellular cGMP. ANP, a peptide secreted by cardiac atrial tissue, is much like other peptide hormones in that it is secreted into the circulatory system and has effects on distant tissues. The principal sites of ANP action are within vascular smooth muscle cells leading to vasodilation and in the kidney glomerulus, where it modulates the rate of filtration, increasing Na+ excretion in the urine. The receptors for the natriuretic factors are integral plasma membrane proteins, whose intracellular domains catalyze the formation of cGMP following natriuretic factor-binding. Intracellular cGMP activates a protein kinase G (PKG), which phosphorylates and modulates enzyme activity, leading to the biological effects of the natriuretic factors.back to the top
Many amino acid and peptide hormones are elaborated by neural tissue, with ultimate impact on the entire system. When their composition was still unknown, hypothalamic secretory products were known as releasing factors, since their effect was to release endocrine hormones from the pituitary. More recently the releasing factors have been renamed releasing hormones. Currently, both names are in common use.
Releasing hormones are synthesized in neural cell bodies of the hypothalamus and secreted at the axon terminals into the portal hypophyseal circulation, which directly bathes the anterior pituitary. These peptides initiate a cascade of biochemical reactions that culminate in hormone-regulated, whole-body biological end points. Cells of the anterior pituitary, with specific receptors for individual releasing hormones, generally respond through a Ca2+, IP3, PKC-linked pathway that stimulates exocytosis of preexisting vesicles containing the various anterior pituitary hormones. The pituitary hormones are carried via the systemic circulation to target tissues throughout the body. At the target tissues they generate unique biological activities.
The secretion of hypothalamic, pituitary, and target tissue hormones is under tight regulatory control by a series of feedback and feed- forward loops. This complexity can be demonstrated using the growth hormone (GH) regulatory system as an example. The stimulatory substance growth hormone releasing hormone (GRH) and the inhibitory substance somatostatin (SS) both products of the hypothalamus, control pituitary GH secretion. Somatostatin is also called growth hormone-inhibiting hormone (GIH). Under the influence of GRH, growth hormone is released into the systemic circulation, causing the target tissue to secrete insulin-like growth factor-1, IGF-1. Growth hormone also has other more direct metabolic effects; it is both hyperglycemic and lipolytic. The principal source of systemic IGF-1 is the liver, although most other tissues secrete and contribute to systemic IGF-1. Liver IGF-1 is considered to be the principal regulator of tissue growth. In particular, the IGF-1 secreted by the liver is believed to synchronize growth throughout the body, resulting in a homeostatic balance of tissue size and mass. IGF-1 secreted by peripheral tissues is generally considered to be autocrine or paracrine in its biological action.
Systemic IGF-1 also has hypothalamic and pituitary regulatory targets. The negative feedback loops cause down-regulation of GH secretion directly at the pituitary. The longer positive feedback loop, involving IGF-1 regulation at the hypothalamus, stimulates the secretion of GIH, which in turn inhibits the secretion of growth hormone by the pituitary. The latter is a relatively unusual negative feed-forward regulatory process. In addition, a shorter negative feedback loop is shown that involves direct IGF-1 action on the pituitary, leading to down-regulation of GH secretion. Similar feedback loops exist for all the major endocrine hormones, and many subtle nuances modulate each regulatory loop.back to the top
The hypothalamus is located below the thalamus and just above the brain stem and is composed of several domains (nuclei) that perform a variety of functions. The hypothalamus forms the ventral portion of the region of the brain called the diencephalon. Anatomically the hypothalamus is divided into three broad domains termed the posterior, tuberal, and anterior regions. Each of these three regions is further subdivided into medial and lateral areas. The various nuclei of the hypothalamus constitute the functional domains of the various hypothalamic areas. A few of the specific nuclei of the hypothalamus include the paraventricular nucleus (PVN) which is located in the anterior medial area and is involved in oxytocin and vasopressin release from the pituitary and the arcuate nucleus of the hypothalamus (ARC, also abbreviated ARH), the dorsomedial hypothalamic nucleus (DMH), and the ventromedial nucleus (VMN) all of which are located in the tuberal medial area. The ARC is involved in control of feeding behavior as well as secretion of various pituitary releasing hormones, the DMH is involved in stimulating gastrointestinal activity, and the VMN is involved in satiety (sensation of being full). The most important overall function of the hypothalamus is to link the central nervous system to the endocrine system via the pituitary gland (also termed the hypophysis). The hypothalamus is involved in the control of certain metabolic processes as well as other functions of the autonomic nervous system. With respect to this discussion the hypothalamus synthesizes and secretes a variety of neurohormones, referred to as hypothalamic-releasing factors, that act upon the pituitary to direct the release of the various pituitary hormones.
Diagrammatic representation of the interactions between the hypothalamus and the pituitary. The hypothalamic releasing and inhibiting hormones exert their effects on the release of anterior pituitary hormones. Oxytocin and vasopressin (antidiuretic hormone) are released directly from hypothalamic axons that terminate in the posterior pituitary, and the hormones are secreted from there directly into the systemic circulation.
The pituitary gland has two lobes called the posterior and anterior lobes. Each lobe secretes peptide hormones that exert numerous effects on the body. Each of the pituitary hormones is described in detail in the following sections. It is the aim of this discussion to provide the background for understanding what pituitary hormones are released and what are the triggers for their release. The posterior pituitary excretes the two hormones, oxytocin and vasopressin. The anterior pituitary secretes six hormones: adrenocortiocotropic hormone (ACTH, also called corticotropin), thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), growth hormone (GH), and prolactin (PRL). The hormone ACTH is derived from a large precursor protein identified as pro-opiomelanocortin (POMC) as describe below. The secretion of the anterior pituitary hormones is under control of the hypothalamus, hence the description of the system as the hypothalamic-pituitary axis. The secretion of the hormones ACTH, TSH, FSH , LH, and GH are stimulated by signals from the hypothalamus, whereas, PRL secretion is inhibited by hypothalamic signals.
The secretion of anterior pituitary hormones results in response to hypophysiotropic hormones that are carried in the portal hypophysial vessels from the hypothalamus to the pituitary. These hypothalamic hormones are commonly referred to as releasing or inhibiting hormones. There are six hypothalamic releasing and inhibiting hormones: corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), luteinizing hormone-releasing hormone (LHRH), growth hormone-releasing hormone (GRH), growth hormone release-inhibiting hormone (GIH, more commonly called somatostatin), and prolactin release-inhibiting hormone (PIH or PIF). Hypothalamic extracts also contain a prolactin-releasing substance (sometimes referred to as prolactin-releasing hormone, PRH). Several peptides found in the hypothalamus (e.g. TRH) can stimulate prolactin secretion so it is as yet unclear whether PRH is the physiologic prolactin-releasing substance. GnRH has been shown to stimulate the release of both FSH and LH and as a consequence the term GnRH is more appropriately used than LHRH.
The hypothalamic releasing and inhibiting hormones are secreted from the median eminence of the hypothalamus. The GnRH-secreting neurons are primarily in the medial preoptic area of the hypothalamus. The somatostatin-secreting neurons reside in the periventricular nuclei. The TRH-secreting and CRH-secreting neurons are found in the medial parts of the periventricular nuclei. The GRH-secreting neurons reside in the arcuate nuclei which is the same region that contains dopamine-secreting neurons. Most of the receptors for the hypophysiotropic hormones are GPCRs.back to the top
The glycoprotein hormones are the most chemically complex family of the peptide hormones. All members of the family are highly glycosylated. Each of the glycoprotein hormones is an (α:β) heterodimer, with the α-subunit being identical in all members of the family. The biological activity of the hormone is determined by the β-subunit, which is not active in the absence of the α-subunit. The α-subunit gene (identified as chorionic gonadotropin, alpha: CGA) is located on chromosome 6q12–q21.
The molecular weight of the gonadotropins (follicle stimulating hormone, FSH; luteinizing hormone, LH, and human chorionic gonadotropin, hCG) is about 25,000 Daltons, whereas that of the thyroid tropic hormone, thyroid stimulating hormone (TSH) is about 30,000. Synthesis of FSH and LH occurs in the same cells of the anterior pituitary and secretion of both is controlled by the hypothalamic decapeptide hormone GnRH. All members of the glycoprotein family transduce their intracellular effects via their respective receptors and the associated G-protein, adenylate cyclase, second-messenger systems. The gonadotropins (LH, FSH and hCG) bind to cells in the ovaries and testes, stimulating the production of the steroid sex hormones estrogen, testosterone (T), and dihydrotestosterone (DHT). The synthesis of the sex hormones is reviewed in the steroid hormone page.
FSH and LH
The FSH β-chain gene (gene symbol = FSHB) is located on chromosome 11p13. The LH β-chain gene (gene symbol = LHB) is located on chromosome 19q13.32. The synthesis and release of FSH and LH is controlled by the action of the hypothalamic releasing factor GnRH. The function of GnRH is to induce an episodic release of both FSH and LH that determines the onset of puberty and ovulation in females. GnRH binds to its receptor on gonadotropes and initiates a signaling cascade that results in release of FSH and LH. The GnRH receptor gene (symbol = GNRHR) is located on chromosome 4q21.2 and encodes a member of the GPCR and Ca2+-dependent receptor family. The control of the hypothalamic-pituitary axis at the level of FSH and LH is controlled by several additional proteins including follistatin, activin, and leptin. Follistatin is a protein that binds to and inhibits proteins of the transforming growth factor-β family (TGFβ) of which activin is a member. Therefore, follistatin inhibits the activity of activin on promoting FSH synthesis and release.
In females FSH stimulates follicular development and estrogen synthesis by granulosa cells of the ovary. In males FSH promotes testicular growth and within the Sertoli cells of the testes it enhances the synthesis and secretion of T and DHT. In females, LH induces thecal cells of the ovary to synthesize estrogens and progesterone and promotes estradiol secretion. The surge in LH release that occurs in mid-menstrual cycle is the responsible signal for ovulation. Continuous LH secretion stimulates the corpus luteum to produce progesterone. In males, LH binds to Leydig cells of the testes to induce the secretion of T.
The FSH receptor (FSHR) is located on chromosome 2p21–p16 spanning 54kbp and contains 10 exons that encode a 678 amino acid glycosylated member of the GPCR family of receptors. Binding of FSH to its receptors results in activation of adenylate cyclase leading to increased PKA activity. The LH receptor is referred to as the LH-choriogonadotropin receptor (LHCGR). The gene for this receptor is also found on chromosome 2p21 and encodes a 674 amino acid glycosylated member of the GPCR family of receptors. The LHCGR contains a large extracellular domain that includes several leucine-rich repeats (LRR). There are other members of the GPCR family that contain LRR in their extracellular domains and this subfamily of receptors is referred to as the LRR-containing GPCR (LRG) family. The LHCGR is coupled a G-protein that activates adenylate cyclase resulting in increased PKA activity. The LHCGR is expressed in the ovary, thecal cells, stromal cells, luteinizing granulosa, and luteal cells of the ovary and in Leydig cells of the testes.
The β-chain gene of hCG (gene symbol = CGB) is located on chromosome 19q13.32. Human chorionic gonadotropin is produced only during pregnancy. The actions of hCG are exerted by binding of the hormone to the LHCGR in the luteal cells of the ovary. Initially the developing embryo synthesizes and secretes hCG. Following implantation the cells of the syncytiotrophoblast (part of the placenta) produce and secrete hCG. The production of hCG increases markedly after implantation; its appearance in the plasma and urine is one of the earliest signals of pregnancy and the basis of many pregnancy tests. The role of hCG during pregnancy is to prevent disintegration of the corpus luteum so as to maintain the synthesis of progesterone by this tissue.back to the top
As indicated above, TSH (also called thyrotropin) is a member of the glycoprotein hormone family and as such is composed of a common α-subunit encoded by the CGA gene and a unique β-chain. The β-chain of TSH is encoded by the TSHB gene (thyroid-stimulating hormone, β-chain) which is on chromosome 1p13 and contains 3 exons, the first of which is non-coding.
Secretion of TSH is stimulated by thyrotropin-releasing hormone (TRH) from the hypothalamus. TRH, a tripeptide, is synthesized by neurons in the supraoptic and supraventricular nuclei of the hypothalamus and stored in the median eminence. TRH is transported to the anterior pituitary via the pituitary portal circulation and binds to a specific receptor located on TSH- and prolactin-secreting cells. There are two TRH receptors, identified as TRH-R1 and TRH-R2, both of which are G-protein coupled receptors (GPCRs). Both TRH receptors are coupled to Gq-type G-proteins. Binding of TRH to its receptor activates a typical PLC-mediated signaling cascade. The TRH-induced signaling leads to TSH secretion as well as increased TSH transcription and post-translational glycosylation. Although both receptors are expressed differentially in the brain and in peripheral tissues, they exhibit indistinguishable TRH-binding affinities. However, only TRH-R1 is expressed at functional levels in the anterior pituitary. The TRH-mediated release of TSH is pulsatile with peak secretion being exerted between midnight and 4am.
The synthesis and release of TSH is controlled by two pathways. The first is exerted by the level of T3 (triiodothyronine) within thyrotropic cells which regulates TSH expression, translation and release. The second regulation is of course exerted by TRH as described above. While in the circulation TSH binds to receptors on the basal membrane of thyroid follicles. The receptors are coupled through G-protein activation of adenylate cyclase as well as PLCβ. The TSH receptor gene (symbol = TSHR) is on chromosome 14q31 and encodes a 764 amino acid glycosylated member of the GPCR family of receptors. The TSHR and the LHCGR proteins share a significant degree of homology. TSH binding to its receptor triggers a signaling cascade that results in increased thyrocyte cAMP, PKA, IP3, and DAG leading to, in the short term, increased secretion of the thyroid hormones, thyroxin (T4) and triiodothyronine (T3). TSH-binding to its receptor also results in increased TSH synthesis and thyroid cell growth.
Chronic stimulation of the TSH receptor causes an increase in the synthesis of a major thyroid hormone precursor, thyroglobulin. Thyroglobulin produced on rough endoplasmic reticulum has a molecular weight of 660,000. It is glycosylated and contains more than 100 tyrosine residues, which become iodinated and are used to synthesize T3 and T4. Thyroglobulin is exocytosed through the apical membrane into the closed lumen of thyroid follicles, where it accumulates as the major protein of the thyroid and where maturation takes place. Mature, iodinated thyroglobulin is taken up in vesicles by thyrocytes and fuses with lysosomes. Lysosomal proteases degrade thyroglobulin releasing amino acids and T3 and T4, which are secreted into the circulation. These compounds are very hydrophobic and require a carrier protein for delivery to target tissues. In the plasma, T3 and T4 are bound to a carrier glycoprotein known as thyroxin-binding globulin and are disseminated throughout the body in this form. The feedback loop that regulates T3 and T4 production is a single short negative loop, with the T3 and T4 being responsible for down-regulating pituitary TSH secretion. Meanwhile, continuously secreted hypothalamic TRH is responsible for up-regulating TSH production. The TSH actually secreted by thyrotropes is the net result of the negative effects of T3 and T4 and the positive effect of TRH.
Thyroid hormones act by binding to cytosolic receptors very similar to steroid hormone receptors, and for this reason T3 and T4 are often classified along with the hydrophobic steroid hormones. The principal role of thyroid hormones is also like that of steroid hormones. In adults, the ligand receptor combination binds to thyroid hormone response elements in nuclear DNA and is responsible for up-regulating general protein synthesis and inducing a state of positive nitrogen balance.
Numerous congenital and acquired forms of hypothyroidism and hyperthyroidism are the result of alterations in the expression, processing, and function of the TSHR. The most common TSHR disorder resulting in hyperthyroidism (thyrotoxicosis) is Graves disease. Graves disease is caused by thyroid-stimulating autoantibodies (TSAb, also called thyroid-stimulating immunoglobulins, TSIs) which bind to and activate the human TSH receptor, leading to the thyrotoxicosis characteristic of this disease. TSAbs bind to the TSH receptor and mimic the TSH stimulation of the gland by increasing intracellular cAMP. The hyperactivated thyroid then secretes excessive T3 and T4. Graves disease is classified as a form of thyrotoxicosis, the name for the clinical syndrome resulting from tissues exposed to high levels of thyroid hormones. One theory proposed for the development of the TSAb is that there is a defect in suppressor T cells that allows helper T cells to stimulate B cells to produce thyroid autoantibodies. The clinical features of Graves disease are thyrotoxicosis, goiter (enlarged thyroid gland), an ophthalmopathy in the form of exophthalmos (eyes bulge out), and dermopathy in the form of pretibial myxedema (localized lesions of the skin, primarily in the lower legs, resulting from the deposition of hyaluronic acid).
At the other end of the spectrum are disorders that lead to hypothyroidism. Deficiency in iodine is the most common cause of hypothyroidism worldwide. Indeed the practice of producing iodized table salt was to stem the occurrence of hypothyroidism. When hypothyroidism is evident in conjunction with sufficient iodine intake it is either autoimmune disease (Hashimoto thyroiditis) or the consequences of treatments for hyperthyroidism that are the cause. In the embryo, thyroid hormone is necessary for normal development and hypothyroidism in the embryo is responsible for cretinism, which is characterized by multiple congenital defects and mental retardation. Because the neurological consequences of congenital hypothyroidism are severe neonatal screening for thyroid hormone levels at birth is routine. Most infants born with congenital hypothyroidism appear normal at birth. However, if left untreated the symptoms will include a thick protruding tongue, poor feeding, prolonged jaundice (which exacerbates the neurological impairment), hypotonia (recognized as "floppy baby syndrome"), episodes of choking, and delayed bone maturation resulting in short stature.back to the top
The POMC gene is located on chromosome 2p23.3. POMC is expressed in both the anterior and intermediate lobes of the pituitary gland. The primary protein product of the POMC gene is a 285 amino acid precursor that can undergo differential processing to yield at least 8 peptides, dependent upon the location of synthesis and the stimulus leading to their production. POMC is produced in the pituitary, the ARC of the hypothalamus, the nucleus of the solitary tract (NTS for Latin term nucleus tractus solitarii; specialized cells within the medulla responsible for sensations of taste and visceral sensations of stretch), as well as in several peripheral tissues such as the skin and reproductive organs. Within the brain neurons that respond to POMC-derived peptides (termed POMCm neurons) are critical in the regulation of overall energy balance via the melanocortin peptides (primarily α-MSH; this is N-terminally acetylated MSH).
The processing of POMC involves glycosylations, acetylations, and extensive proteolytic cleavage at sites shown to contain regions of basic protein sequences. The proteases that recognize these cleavage sites are tissue-specific; thus, the physiologically active product of the anterior pituitary is ACTH (discussed in detail in the section below). Aside from ACTH, the activities of the melanocortins (primarily α-MSH) produced in the anterior pituitary are the best understood peptides derived from the POMC mRNA. The activities of the melanocortin peptides is discussed in the section following ACTH.
Processing of the POMC precursor protein. Cleavage sites consist of the sequences, Arg-Lys, Lys-Arg or Lys-Lys. Enzymes responsible for processing of POMC peptides include prohormone convertase 1/3 (PC1/3), prohormone convertase 2 (PC2), carboxypeptidase E (CPE), peptidyl α-amidating monooxygenase (PAM), N-acetyltrasferase (N-AT), and prolylcarboxypeptidase (PRCP). Adrenocorticotropic hormone (ACTH) and β-lipotropin are products generated in the corticotrophic cells of the anterior pituitary under the control of corticotropin releasing hormone (CRH). Alpha-melanocyte stimulating hormone (α-MSH), corticotropin-like intermediate lobe peptide (CLIP), γ-lipotropin and β-endorphin are products generated in the intermediate lobe of the pituitary under the control of dopamine. α-, β- and γ-MSH are collectively referred to as melanotropin or intermedin. The green shaded boxes represent the heptapeptide sequence that constitutes the MSH core.
Many of the other POMC products are synthesized in other neural tissues that contain proteases with appropriate specificity. In human embryos and in pregnant women, the intermediate lobe is active and leads to the production of endorphins and enkephalins. These same endorphin-producing pathways are active in other neural tissues, and since they bind to the opioid receptors in other parts of the brain they are assumed to represent natural opioid-like analgesic compounds.back to the top
ACTH is a 39 amino acid peptide that is derived by post-translational modification from the 241 amino acid preproprotein, POMC. ACTH is the main physiologically active product of the actions of the hypothalamic releasing hormone, CRH, on the anterior pituitary. Although CRH is the primary stimulus for ACTH release, other hormones also exert effects on ACTH release. CRH stimulates a pulsatile secretion of ACTH with peak levels seen before waking and declining as the day progresses. Negative feedback on ACTH secretion is exerted by cortisol at both the hypothalamic and anterior pituitary levels. Thus, the primary product of the systemic actions of ACTH regulates the further actions of this corticotropic hormone. Additional factors that influence ACTH secretion include physical, emotional, and chemical stresses. These stressors include pain, cold exposure, acute hypoglycemia, trauma, depression, and surgery. The stress-mediated increases in ACTH secretion are the result of the actions of vasopressin and CRH.
The biological role of ACTH is to stimulate the production of adrenal cortex steroids, principally the glucocorticoids cortisol and corticosterone. ACTH also stimulates the adrenal cortex to produce the mineralocorticoid, aldosterone as well as the androgen, androstenedione. ACTH exerts its effects on the adrenal cortex by binding to a specific receptor that is a member of the melanocortin receptor family. The ACTH receptor is identified as MC2R for melanocortin-2 receptor. The ACTH receptor is a Gs-type G-protein coupled receptor (GPCR) and ACTH binding triggers activation of adenylate cyclase, elevation of cAMP, and increased PKA activity of adrenal cortex tissue. The main effect of these events is to increase the activity of CYP11A1 (also called P450-linked side chain-cleaving enzyme, P450ssc, 20,22-desmolase, or cholesterol desmolase), which converts cholesterol to pregnenolone during steroid hormone synthesis. Because of the distribution of enzymes in the various adrenal cortex subdivisions, the principal physiological effect of ACTH is production of the glucocorticoids.
Secondary adrenal insufficiency occurs in patients with deficiencies in pituitary ACTH production or secretion. Whereas, primary adrenal insufficiency (adrenal hypoplasia) is characteristic of Addison disease which was originally diagnosed as the result of lesions in the adrenal glands caused by tuberculosis. Secondary adrenal insufficiency is characterized by weakness, fatigue, nausea, vomiting, and anorexia. On the opposite side of the abnormal ACTH spectrum are the adrenal hyperplasias. These include the congenital adrenal hyperplasias (CAH) and Cushing syndrome. The CAH are a family of inherited disorders that result from loss-of-function mutations in one of several genes involved in adrenal steroid hormone synthesis. Endogenous causes of Cushing syndrome are pituitary corticotrope adenomas resulting in excess ACTH production and secretion. The characteristic features of Cushing syndrome are psychiatric disturbances (depression, mania, and psychoses), central obesity, hypertension, diabetes, moon-shaped face, thin fragile skin, easy bruising, and purple striae (stretch marks). In addition, Cushing syndrome patients manifest with gonadal dysfunction that is characteristic of hyperandrogenism with excess body and facial hair (hirsutism) and acne.back to the top
The POMC-derived melanocortin peptides include α-MSH, β-MSH, γ-MSH, ACTH1-24, and ACTH1-13–NH2 (desacetyl-α-MSH; indicated as des-α-MSH in above Figure). The POMC-derived melanocortins belong to a family of peptides referred to as the melanocortin system. This system includes the POMC-derived melanocortins which exhibit agonist activities, the antagonist peptide agouti-related peptide (AgRP), the melanocortin receptors (MCR), and the melanocortin receptor accessory proteins (MRAPs). The MCR family of receptors consists of five identified members termed MC1R through MC5R.
The melanocortin system has been shown to be critical in the regulation of food intake and energy expenditure via a number of different assay systems involving both humans and animals. The details of the role of melanocortins in appetite regulation are discussed in the Gut-Brain Interactions page.back to the top
The principal hormones of the posterior pituitary are the nonapeptides oxytocin and vasopressin (also called arginine vasopressin, AVP). The amino acid sequences of vasopressin and oxytocin differ by only two amino acids. Both of these hormones are synthesized as prohormones in neural cell bodies of the hypothalamus and mature as they pass down axons in association with carrier proteins termed neurophysins. The axons terminate in the posterior pituitary, and the hormones are secreted directly into the systemic circulation. The neurophysins themselves are derived from the oxytocin and vasopressin pre-pro-proteins. The oxytocin pre-pro-protein contains neurophysin I and the vasopressin pre-pro-protein contains neurophysin II. The human genes coding for pre-provasopressin-neurophysin II (prepro-AVP-NPII) and prepro-oxytocin-neurophysin I (prepro-OT-NPI) are similar in their intron-exon structure and they are linked together with 12kb of intervening DNA. Interestingly, the two genes are transcribed from opposite DNA strands.
Vasopressin is also known as antidiuretic hormone (ADH), because it is the main regulator of body fluid osmolarity. The designation arginine vasopressin is used when discussing vasopressins from different mammals as marsupials and pigs produce a vasopressin peptide where the arginine is replaced by a lysine and is thus, referred to as lysine vasopressin. The secretion of vasopressin is regulated in the hypothalamus by osmoreceptors which sense water and Na+ concentration and stimulate increased vasopressin secretion when plasma osmolarity increases. The secreted vasopressin increases the reabsorption rate of water in kidney tubule cells, causing the excretion of urine that is concentrated in Na+ and thus yielding a net drop in osmolarity of body fluids. Vasopressin deficiency leads to production of large volumes of watery urine and to polydipsia (increased desire for fluid intake). These symptoms are diagnostic of a condition known as diabetes insipidus. Diabetes insipidus has numerous causes that include effects on both the pituitary and kidneys.
Vasopressin binds plasma membrane receptors which activate signaling events through G-proteins coupled to the cAMP second messenger system or through the PLCβ pathway. There are three kinds of vasopressin receptors designated V1A (V1A), V1B (V1B), and V2 (V2). The V1A (gene symbol: AVPR1A) and V1B (gene symbol: AVPR1B) receptors signal via GPCRs that activate Gq-type G-proteins leading to hydrolysis of PIP2 resulting in increased intracellular Ca2+ concentration. The V1B receptor is also commonly referred to as the V3 receptor. The V2 (gene symbol: AVPR2) receptors signal via GPCRs that activate Gs-type G-proteins leading the activation of adenylate cyclase resulting in increased cAMP levels. V1 receptors are found in blood vessels and vasopressin binding triggers vascular contraction resulting in increased blood pressure. The V2 receptors are found primarily in the collecting ducts of the kidneys and are responsible for triggering vasopressin-mediated water retention, thereby, affecting osmolarity. Mutations in the gene encoding the V2 receptor are responsible for X-linked nephrogenic diabetes insipidus.
Oxytocin is produced in the magnocellular neurosecretory cells of the hypothalamus and is then stored in axon terminals of the anterior pituitary. While stored in the pituitary, oxytocin is bound to neurophysin I in Herring bodies. Secretion of oxytocin is stimulated by electrical activity of the oxytocin cells of the hypothalamus. The actions of oxytocin are elicited via the interaction of the hormone with high affinity receptors. The oxytocin receptor (gene symbol: OXTR) is a GPCR whose affinity for ligand is dependent upon Mg2+ and cholesterol, both of which act as positive allosteric regulators. Oxytocin secretion in nursing women is stimulated by direct neural feedback obtained by stimulation of the nipple during suckling. This response to oxytocin is referred to as the "let-down response". Its physiological effects include the contraction of mammary gland myoepithelial cells, which induces the ejection of milk from mammary glands. The other primary action of oxytocin is the stimulation of uterine smooth muscle contraction leading to childbirth. The uterine effect of oxytocin is due, in part, to increased production and release of the prostaglandin PGF2α from the myometrium and to a lesser extent from the decidua.
In males the circulating levels of oxytocin increase at the time of ejaculation. It is believed that the increase in oxytocin levels causes increased contraction of the smooth muscle cells of the vas deferens thereby propelling the sperm toward the urethra.back to the top
Growth hormone (GH), human chorionic somatomammotropin, hCS (also called human placental lactogen, hPL), and prolactin (PRL) comprise the growth hormone family. All have about 200 amino acids, 2 disulfide bonds, and no glycosylation. Although each has special receptors and unique characteristics to their activity, they all possess growth-promoting and lactogenic activity. Mature GH (22,000 daltons) is synthesized in acidophilic pituitary somatotropes as a single polypeptide chain. Because of alternate RNA splicing, a small amount of a somewhat smaller molecular form is also secreted. Growth hormone and hCS are proteins encoded by genes in a cluster of five genes termed the human growth hormone/human chorionic somatomammotropin (GH/CS) gene cluster that spans 6.6kbp on chromosome 17q22–q24. In addition to the GH gene (symbol = GHN) and CS genes (gene symbol = CSA), this gene cluster contains the chorionic somatomammotropin hormone 2, CSH2 gene (gene symbol = CSB), the chorionic somatomammotropin-like1 , CSHL1 gene (gene symbol = CSL), and the growth hormone 2, GH2 gene (gene symbol = GHV which stands for growth hormone variant). Expression of GH occurs only in the pituitary whereas, the other four genes in the GH/CS gene cluster are expressed only in placental tissues.
Humans respond to natural or recombinant human or primate growth hormone with appropriate secretion of IGF-1, but growth hormone of other species has no normal biological effect in man. The latter is puzzling because interspecies GH homologies are quite high in many cases, and most other species respond well to human growth hormone. In humans, growth hormone promotes gluconeogenesis and is consequently hyperglycemic. It promotes amino acid uptake by cells, with the result that GH therapy puts an organism into positive nitrogen balance, similar to that seen in growing children. Finally, growth hormone is lipolytic, inducing the breakdown of tissue lipids and thus providing energy supplies that are used to support the stimulated protein synthesis induced by increased amino acid uptake.
There are a number of genetic deficiencies associated with GH. GH-deficient dwarfs lack the ability to synthesize or secrete GH, and these short-statured individuals respond well to GH therapy. Pygmies lack the IGF-1 response to GH but not its metabolic effects; thus in pygmies the deficiency is post-receptor in nature. Finally, Laron dwarfs have normal or excess plasma GH, but lack liver GH receptors and have low levels of circulating IGF-1. The defect in these individuals is clearly related to an inability to respond to GH by the production of IGF-1. The production of excessive amounts of GH before epiphyseal closure of the long bones leads to gigantism, and when GH becomes excessive after epiphyseal closure, sacral bone growth leads to the characteristic features of acromegaly.back to the top
Human chorionic somatomammotropin is produced by the placenta late in gestation. This hormone has also been called human placental lactogen (hPL) and chorionic growth hormone-prolactin (CGP). The hCS gene is found in the human growth hormone/human chorionic somatomammotropin (GH/CS) gene cluster as described above in the Growth Hormone section. The amino acid composition of hCS is similar to human growth hormone. Evidence suggests that due to the similarities between growth hormone, hCS and prolactin they likely evolved from a single progenitor hormone gene. At its height the hormone is secreted at a rate of about 1 g/day, the highest secretory rate of any known human hormone. However, little hCS reaches the fetal circulation. The amount of hCS that is secreted is proportional to the size of the placenta. Low levels of hCS during pregnancy are a sign of placental insufficiency. The biological actions of hCS are similar to those of growth hormone suggesting that it functions as a maternal growth hormone of pregnancy. The hormone induces the retention of potassium, calcium, and nitrogen, decreases glucose utilization and increases lipolysis.back to the top
Prolactin is produced by acidophilic pituitary lactotropes. The PRL gene is located on chromosome 6p22.2–p21.3. Two promoter elements have been identified in the PRL gene that are located 5.5kbp apart. The 5'-promoter directs the expression of prolactin in decidualized endometrium as well as in lymphoblastoid cells. The more proximal promoter directs pituitary lactotrope expression and this promoter is controlled by the activity of the POU-domain transcription factor, PIT1. Although the PRL gene is thought to have evolved from an ancestral hormone gene common to GH and hCS, prolactin only shares 16% amino acid homology to these other two hormones. The prolactin protein is 198 amino acids in length with a molecular weight of 22,000 Daltons. Prolactin is known to bind zinc (Zn2+) and the binding of this metal stabilizes prolactin in the secretory pathway. Prolactin is the lone tropic hormone of the pituitary that is routinely under negative control by prolactin release-inhibiting hormone (PIH or PIF), which is, in fact, the catecholamine neurotransmitter, dopamine. Decreased hypophyseal dopamine production, or damage to the hypophyseal stalk, leads to rapid up-regulation of PRL secretion. A number of other hypothalamic releasing hormones induce increased prolactin secretion; as a result, it is unclear whether a specific PRH exists for up-regulating PRL secretion. Prolactin does not appear to play a role in normal gonadal function yet hyperprolactinemia in humans results in hypogonadism.
Prolactin secretion increases during pregnancy and promotes breast development in preparation for the production of milk and lactation. Although prolactin serves this important function in breast development during pregnancy there is no evidence to indicate that it functions during normal breast tissue development before or during puberty. During pregnancy the increased production of estrogen enhances breast development but it also suppresses the effects of prolactin on lactation. Following parturition (birth) estrogen (as well as progesterone) levels fall allowing lactation to occur. This is to ensure that lactation is not induced until the baby is born.back to the top
The pancreatic polypeptide (PP) family of hormones comprises two gut hormones, pancreatic polypeptide (PP) and peptide tyrosine-tyrosine (PYY), as well as the central nervous system hormone neuropeptide Y (NPY). Each of these peptide hormones contains 36 amino acids consisting of numerous tyrosines (hence the Y peptides nomenclature) and an α-amidation at the C-terminus. The three-dimensional structure of these hormones includes a hairpin-like motif referred to as the pancreatic polypeptide fold (PP-fold). The PP-fold is required for interaction of the hormones with specific G-protein coupled receptors (GPCRs).
Details of the actions of PP, PYY, and NPY are discussed in the Gut-Brain Interactions page.back to the top
Melanin-concentrating hormone (MCH) was originally identified as a 19 amino acid cyclic peptide that induced the lightening of the skin in fish. Subsequently the peptide was identified in rodents to be over-expressed in response to fasting and also elevated in genetically obese mice (ob/ob mice).
Details of the actions of MCH are discussed in the Gut-Brain Interactions page.back to the top
The orexins constitute two neuroendocrine peptides derived from the same gene. These peptides are designated orexin A and orexin B. Details of the actions of the orexins are discussed in the Gut-Brain Interactions page.back to the top
There are more than 30 peptides currently identified as being expressed within the digestive tract, making the gut the largest endocrine organ in the body. The regulatory peptides synthesized by the gut include hormones, peptide neurotransmitters and growth factors. Indeed, several hormones and neurotransmitters first identified in the central nervous system and other endocrine organs have subsequently been found in endocrine cells and/or neurons of the gut. Visit the Table of Vertebrate Hormones page to see a more complete list of gastrointestinal peptides and hormones.
|Cholecystokinin (CCK)||enteroendocrine I cells predominantly of the duodenum, jejunum||stimulates gallbladder contraction and bile flow; increases secretion of digestive enzymes from pancreas; vagal nerves in the gut express CCK1 (CCKA) receptors|
|Enterostatin||derived from N-terminal end of pancreatic colipase; pentapeptide human enterostatin contains the sequence: APGPR||regulates fat intake; peripheral or central administration inhibits consumption of a high-fat diet but not a low-fat diet|
|FGF19||gallbladder, duodenum, ileum||member of the large FGF family of growth factors; expression of FGF19 gene activated by transcription factor FXR, FXR is activated when ileal enterocytes absorb bile acids, when released to the portal circulation FGF19 stimulates hepatic glycogen and protein synthesis while inhibiting glucose production; reduces the expression and activity of CYP7A1 which is the rate-limiting enzyme in bile acid synthesis; acts in the gallbladder to induce relaxation and refilling with bile acids|
|Gastrin||made in enteroendocrine G cells of the gastric antrum and duodenum||gastric acid and pepsin secretion; exists in two major forms: little gastrin (17 amino acids) and big gastrin (34 amino acids), both result from a single precursor protein of 101 amino acid; both species contain a Y residue in the C-terminal portion of the protein that may be either sulfated (gastrin II) or nonsulfated (gastrin I); both forms bind to the CCK2 (CCKB) receptor on stomach and gut parietal cells with an affinity equal to that of CCK; the C-terminal tetrapeptide of both gastrins and CCK are identical and possess all the biological activities of both gastrin and CCK|
|Gastrin-releasing peptide (GRP), is a bombesin-related peptide; also called neuromedin B||stomach, duodenum||released from vagal nerve; stimulates release of gastrin from G cells of the stomach and CCK from small intestinal enteroendocrine I cells|
|Ghrelin||primary site is X/A-like enteroendocrine cells of the stomach oxyntic (acid secreting) glands, minor synthesis in intestine, pancreas and hypothalamus||regulation of appetite (increases desire for food intake); energy homeostasis; glucose metabolism; gastric secretion and emptying, insulin secretion|
|Glucagon-like peptide 1 (GLP-1)||enteroendocrine L cells predominantly in the ileum and colon||potentiates glucose-dependent insulin secretion; inhibits glucagon secretion; inhibits gastric emptying|
|Glucagon-like peptide 2 (GLP-2)||enteroendocrine L cells predominantly in the ileum and colon||enhances digestion and food absorption; inhibits gastric secretions; promotes intestinal mucosal growth|
|Glucose-dependent insulinotropic polypeptide (GIP), originally called gastric inhibitory polypeptide||enteroendocrine K cells of the duodenum and proximal jejunum||inhibits secretion of gastric acid; enhances insulin secretion|
|Motilin||proximal small intestine||initiates inter-digestive intestinal motility; stimulates release of PP; stimulates gallbladder contractions|
|Obestatin||primary site is stomach, minor synthesis in intestine||derived from pro-ghrelin protein; acts in opposition to ghrelin action on appetite|
|Oxyntomodulin||enteroendocrine L cells predominantly in the ileum and colon||contains all of the amino acids of glucagon (see Figure below); inhibits meal-stimulated gastric acid secretion similar to GLP-1 and GLP-2 action; induces satiety, decreases weight gain, and increases energy consumption; has weak affinity for GLP-1 receptor as well as the glucagon receptor, may mimic glucagon actions in liver and pancreas|
|Pancreatic polypeptide: PP||pancreas F cells, colon and rectum||inhibits pancreatic bicarbonate and protein secretion|
|Peptide tyrosine tyrosine (PYY)||enteroendocrine L cells predominantly in the ileum and colon||reduced gut motility; delays in gastric emptying, and an inhibition of gallbladder contraction; exerts effects on satiety via actions in the hypothalamus|
|Secretin||enteroendocrine S cells of the duodenum, jejunum||pancreatic bicarbonate secretion; inhibits gastric secretions; stimulates PP secretion|
|Somatostatin||made by D cells of the gut and δ-cells of the pancreas, also produced in hypothalamus and other organ systems||inhibits release and action of numerous gut peptides, e.g. CKK, OXM, PP, gastrin, secretin, motilin, GIP; also inhibits insulin and glucagon secretion from pancreas|
|Substance P, a member of the tachykinin family that includes neurokinin A (NKA) and neurokinin B (NKB)||entire gastrointestinal tract||CNS function in pain (nociception); involved in vomit reflex; stimulates salivary secretions; induces vasodilation antagonists; have anti-depressant properties|
|Vasoactive intestinal peptide (VIP)||pancreas||smooth muscle relaxation; stimulates pancreatic bicarbonate secretion|
Adipose tissue is not merely an organ designed to passively store excess carbon in the form of fatty acids esterified to glycerol (triacylglycerols). More complete information on the roles of adipose tissue in overall metabolism and inflammation can be found in the Adipose Tissue page.
Mature adipocytes synthesize and secrete numerous enzymes, growth factors, cytokines and hormones that are involved in overall energy homeostasis. Many of the factors that influence adipogenesis are also involved in diverse processes in the body including lipid homeostasis and modulation of inflammatory responses. In addition, a number of proteins secreted by adipocytes play important roles in these same processes. In fact recent evidence has demonstrated that many factors secreted from adipocytes are proinflammatory mediators and these proteins have been termed adipocytokines or adipokines. Members of this class of protein secreted from adipocytes include TNF-α, IL-6 and leptin. Listed in the Table below is only a subset of proteins known to be secreted by adipose tissue and the focus is on those that effect overall metabolic homeostasis and modulate inflammatory processes. As is clear from the Table, not all the proteins are unique to adipose tissue. Details of the structure and function of several proteins follows the Table.
|Factor||Principal Source||Major Action|
|Leptin||predominantly adipocytes, mammary gland, intestine, muscle, placenta||see Adipose Tissue page|
also called adipocyte complement factor 1q-related protein (ACRP30), and adipoQ
|adipocytes||see Adipose Tissue page|
|IL-6||adipocytes, hepatocytes, activated Th2 cells, and antigen-presenting cells (APCs)||acute phase response, B cell proliferation, thrombopoiesis, synergistic with IL-1 and TNF on T cells|
|TNFα||primarily activated macrophages, adipocytes||induces expression of other autocrine growth factors, increases cellular responsiveness to growth factors and induces signaling pathways that lead to proliferation|
|Resistin||adipocytes, spleen, monocytes, macrophages, lung, kidney, bone marrow, placenta||see Adipose Tissue page|
|Adipsin (also called complement factor D)||adipocytes, liver, monocytes, macrophages||rate limiting enzyme in complement activation|
|monocyte chemotactic protein-1 (MCP-1)||leukocytes, adipocytes||is a chemokine defined as CCL2 (C-C motif, ligand 2); recruits monocytes, T cells, and dendritic cells to sites of infection and tissue injury|
|plasminogen-activator inhibitor-1 (PAI-1)||adipocytes, monocytes, placenta, platelets, endometrium||see the Blood Coagulation page for more details|
|C-reactive protein (CRP)||hepatocytes, adipocytes||is a member of the pentraxin family of calcium-dependent ligand binding proteins; assists complement interaction with foreign and damaged cells; enhances phagocytosis by macrophages; levels of expression regulated by circulating IL-6; modulates endothelial cell functions by inducing expression of various cell adhesion molecules, e.g. ICAM-1, VCAM-1, and selectins; induces MCP-1 expression in endothelium; attenuates NO production by downregulating NOS expression; increase expression and activity of PAI-1|
Irisin, named after the Greek Goddess Iris, messenger of the Olympian Gods, was discovered in studies aimed at defining mechanisms by which exercise results in improvement in metabolic status in obesity and type 2 diabetes. Exercise has been shown to increase whole body energy expenditure in excess of the calories that are required for the actual work performed. Related studies in mice demonstrated that muscle-specific expression of the transcriptional co-activator PGC-1α results in resistance to age-related obesity and diabetes. PGC-1α was initially identified as a peroxisome proliferator-activated receptor-gamma (PPARγ)-interacting protein from brown adipose tissue (BAT) that was involved in regulating the process of adaptive thermogenesis in response to cold. Subsequent studies determined that the primary function of PGC-1α was to stimulate mitochondrial biogenesis and oxidative metabolism.
The role of exercise in improving metabolic status in tissues other than skeletal muscle suggested that a protein was secreted from exercising muscle and acting on tissues such as adipose tissue and liver. In studies in mice it was found that PGC-1α expression in muscle stimulates an increase in expression of a membrane protein called FNDC5, fibronectin type III domain-containing protein 5. When FNDC5 is expressed in skeletal muscle, in response to PGC-1α activation, it is cleaved and secreted as the hormone, irisin. The FNDC5 gene is located on chromosome 1p35.1 encoding a 203 amino acid protein. When cleaved from FNDC5, irisin contains 110 amino acids. The amino acid sequences of irisin are highly conserved with human and mouse proteins being 100% identical. This high amino acid conservation implies a highly conserved function that is likely to be mediated by irisin binding to a cell surface receptor. The identity of an irisin receptor is as yet unknown. The highest basal levels of expression of FNDC5 are seen in brain and heart, with low basal expression in liver, lung, skeletal muscle, and testis.
Irisin expression and secretion is induced in response to exercise and activates profound changes in the subcutaneous white adipose tissue (WAT), stimulating expression of uncoupling protein 1 (UCP1) and results in a broad program of brown fat-like development. These BAT-like cells induced in WAT are most commonly referred to as beige or brite fat cells. Importantly, this causes a significant increase in total body energy expenditure and resistance to obesity-linked insulin resistance. Even moderate increases in serum levels of irisin result in increases in energy expenditure in mice with no changes in physical activity or food intake. Similarly, irisin is induced with exercise in humans. The actions of irisin recapitulate many of the most important benefits of exercise and muscle activity.
The activity of irisin at inducing brown thermogenesis in WAT is quite profound being able to result in increased levels of UCP1 mRNA ranging from 7-500 fold. In addition to induction of UCP1, irisin activates the expression of several other BAT genes such as elongation of very long-chain fatty acids 3 (ELOVL3), cytochrome c oxidase polypeptide 7A1 (COX7A1), and otopetrin 1 (OTOP1). Conversely, genes such as leptin, that are characteristic of white fat development, are downregulated in response to irisin. In addition to the induction of BAT-like cells in WAT, irisin activity is associated with a large increase in oxygen consumption, improvement in glucose tolerance, and a reduction in fasting insulin. These activities of irisin illustrate that the hormone is a significant effector of increased energy expenditure, improved diet-induced insulin resistance, and reduced body weight.
The therapeutic potential of irisin is obvious. Exogenously administered irisin can induce the browning of subcutaneous fat and thermogenesis, and it presumably could be prepared and delivered as an injectable polypeptide. Increased formation of brown or beige/brite fat has been shown to have anti-obesity and antidiabetic effects and adult humans have significant deposits of UCP1-positive brown fat.back to the top
Natriuresis refers to enhanced urinary excretion of sodium. This can occur in certain disease states and through the action of diuretic drugs. At least 3 natriuretic hormones have been identified. Atrial natriuretic factor (ANF: also called atrial natriuretic peptide, ANP) was the first cardiac natriuretic hormone identified. This hormone is secreted by cardiac muscle when sodium chloride intake is increased and when the volume of the extracellular fluid expands. Specifically, ANP is released from the right atrium of the heart in response to increased venous volume returning to the heart via the inferior and superior vena cavae. Active ANP is a 28-amino acid peptide containing a 17-amino acid ring formed by intrachain disulfide bonding. Two smaller forms of ANP have also been isolated from the brain. A second natriuretic peptide (originally called BNP since it was first isolated from porcine brain) has been identified and found in human heart and blood (but not human brain). BNP is a 32-amino acid peptide and has different amino acids in its 17-amino acid ring as well as being encoded for by a different gene. Although the acronym BNP is still commonly used, the protein is now known as B-type natriuretic peptide or also ventricular natriuretic peptide (but still with the BNP acronym). In humans, a third natriuretic peptide (CNP) is present in the brain but not in the heart.
The action of ANP is to cause natriuresis presumably by increasing glomerular filtration rate (its exact mechanism of action remains unclear). ANP induces relaxation of the mesangial cells of the glomeruli and thus may increase the surface area of these cells so that filtration is increased. Alternatively, ANP might act on tubule cells to increase sodium excretion. Other effects of ANP include reducing blood pressure, decreasing the responsiveness of adrenal glomerulosa cells to stimuli that result in aldosterone production and secretion, inhibit secretion of vasopressin and decreasing vascular smooth muscle cell responses to vasoconstrictive agents. These latter actions of ANP are counter to the effects of angiotensin II. In fact, ANP also lowers renin (see next section) secretion by the kidneys thus, lowering circulating angiotensin II levels.
ANP is encoded by the natriuretic peptide A gene (symbol: NPPA) which is located on chromosome 1p36.21 and is composed of 3 exons that encode a 151 amino acid preproprotein. Expression of the NPPA gene occurs primarily in cardiac atrial myocytes but lower levels of expression also occur in the brain, kidney, uterus, and lung. Following synthesis and removal of the signal peptide, the pro-ANP protein is stored in secretory vesicles. Upon stimulated release the cardiac transmembrane serine protease, corin, cleaves pro-ANP releasing the mature form of ANP (28 amino acids) from the C-terminus of pro-ANP. BNP is encoded by the natriuretic peptide B gene (symbol: NPPB) which is located on chromosome 1p36.2 and is composed of 3 exons that encode a 134 amino acid preproprotein. Expression of the NPPB gene occurs primarily in cardiac ventricular myocytes. Like the processing of prepro-ANP, following synthesis of prepro-BNP the signal peptide (25 amino acids) is removed and pro-BNP is stored intracellularly. BNP is carbohydrate modified by O-glycosylation. Biologically active BNP (32 amino acids and referred to as BNP-32) is cleaved from pro-BNP by either corin (as for ANP) or by furin. Furin is a protease that is a member of the subtilisin-like proprotein convertase family of proteases.
Three different ANP receptors have been identified: ANPR-A (encoded by the NPR1 gene), ANPR-B (encoded by the NPR2 gene), and ANPR-C (encoded by the NPR3 gene). When ANP or BNP bind to receptor, an increase in guanylate cyclase activity results leading to production of cyclic GMP (cGMP). Both ANPR-A and ANPR-B proteins span the plasma membrane and their intracellular domains possess the intrinsic guanylate cyclase activity. ANP and BNP are the natural ligands for the ANPR-A receptor and bind with relatively equivalent affinity and elicit the same responses. CNP is the ligand for the ANPR-B receptor. The function of the ANPR-C protein is to serve as a clearance receptor removing natriuretic peptides from the blood via receptor-mediated endocytosis.back to the top
The renin-angiotensin system (also commonly called the renin-angiotensin-aldosterone system, RAAS) is responsible for regulation of blood pressure. Bioactive angiotensin is derived from the precursor protein, angiotensinogen, produced by the liver. Renin is a protease produced by the kidneys and is responsible for cleavage of angiotensinogen initiating the production of bioactive angiotensin. The intra-renal baroreceptor system is a key mechanism for regulating renin secretion. A drop in pressure results in the release of renin from granular cells in the wall of the afferent arteriole at the base of the glomerulus in the juxtaglomerular apparatus. These are the only cells in the human body that synthesize and secrete renin. Renin secretion is also regulated by the rate of Na+ and Cl– transport across the macula densa. The higher the rate of transport of these ions the lower the rate of renin secretion. The only function for renin (an aspartyl protease) is to cleave a 10-amino acid peptide from the N-terminal end of angiotensinogen. This cleaved decapeptide is called angiotensin I.
Angiotensin I is then cleaved by the action of angiotensin-converting enzyme (ACE: a membrane-bound Zn2+-dependent dicarboxypeptidase) generating the bioactive octapeptide hormone, angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe). The function of ACE is to remove two amino acids from the C-terminal end of angiotensin I. Angiotensin-converting enzyme is highly expressed by vascular endothelial cells, renal proximal tubular epithelial cells, ciliated intestinal epithelial cells, lung epithelia, and developing male germ cells. Expression is also found in several areas of the brain and in the choroid plexus. When monocytes differentiate to macrophages, and when dendritic cells are immunologically activated, expression of ACE is induced. Unlike renin which has a single substrate, ACE exhibits activity to a wide range of substrates ranging in size from tripeptides to proteins of 42 amino acids. The major substrates for ACE are angiotensin I and bradykinin, both of which are involved in the regulation of blood pressure.
Angiotensin II can be cleaved by another membrane-bound Zn2+-dependent peptidase (glutamyl aminopeptidase, also known as aminopeptidase A), which removes one amino acid from the N-terminal end generating the heptapeptide hormone angiotensin III (Arg-Val-Tyr-Ile-His-Pro-Phe). The vasopressive activity of angiotensin III is similar, but less potent, than angiotensin II and is exerted by binding to the same receptors to which angiotensin II binds. Like angiotensin II, angiotensin III exerts effects leading to increased blood pressure. Whereas, angiotensin II exerts its effects equivalently on several target tissues, angiotensin III is most potent via actions within the central nervous system. Indeed, evidence indicates that angiotensin III is the primary effector of the renin-angiotensin system in the control of blood pressure via the central sympathetic nervous system.
The renin gene (symbol: REN) is located on chromosome 1q32 and is composed of 10 exons that encode a 406 amino acid preproprotein. Removal of the signal peptide (20 amino acids) and the pro portion (46 amino acids) of prorenin results in the production of the 340 amino acid active form of the enzyme. Several alternative mRNAs are generated from the REN gene via alternative promoter usage and via alternative splicing. However, the function of these alternative mRNAs is not fully defined. The angiotensin-converting enzyme gene (symbol: ACE) is located on chromosome 17q23.3 and is composed of 26 exons that generate three alternatively spliced mRNAs, each of which generate a distinct ACE isoform. ACE isoform 1 is referred to as the endothelial or somatic form and is a 1306 amino acid precursor. The ACE isoform 2 is referred to as the testicular form and is a 732 amino acid precursor.
Angiotensin II was originally identified as hypertensin and angiotonin. It is one of the most potent naturally occurring vasoconstrictors. In addition to its effects on the vasculature, angiotensin II (and its derivative angiotensin III) acts on the kidneys to increase renal tubular Na+ and Cl– reabsorption, water retention, and K+ excretion, on the posterior pituitary to induce the release of vasopressin (anti-diuretic hormone, ADH), stimulates the zona glomerulosa cells of the adrenal cortex to secrete aldosterone, and exerts effects in the central nervous system resulting in increased sympathetic activity. The vasoconstrictive action of angiotensin II is primarily exerted on the arterioles and leads to a rise in both systolic and diastolic blood pressure. It is this action of angiotensin II on blood pressure that led to the development of a class of drugs called the ACE inhibitors for use as anti-hypertensive drugs. As the name implies, ACE inhibitors prevent ACE from converting angiotensin I to angiotensin II. All of the drugs that inhibit the activity of ACE contain the suffix "–pril", e.g. captopril. One side-effect of the use of ACE inhibitors is a persistent dry cough leading to lack of compliance with the drug in a number of patients. The cause of the dry cough is due to reduced degradation of bradykinin, a known substrate for ACE. Although bradykinin is primarily involved in the contractile activity of vascular smooth muscle, it also induces constriction of the bronchioles in the lungs and it is this latter activity that contributes to the dry cough with the use of ACE inhibitors.
In individuals that are depleted of sodium or who have liver disease (e.g. cirrhosis), the pressive actions of angiotensin II are greatly reduced. These conditions lead to increased circulating levels of angiotensin II which in turn leads to a down-regulation in the numbers of angiotensin II receptors on smooth muscle cells. As a consequence, administration of exogenous angiotensin II to these individuals has little effect. In addition to the other physiological responses to angiotensin II indicated, angiotensin II affects the contractility of the mesangial cells of the kidney leading to decreased glomerular filtration rate. One additional effect of angiotensin II is to potentiate the release of norepinephrine.
Two distinct types of angiotensin II receptors have been identified, AT1R and AT2R. The AT1R is a classical serpentine G-protein coupled receptor (GPCR). The AT1R is coupled to both a Gq-protein that leads to activation of PLCβ, and a Gi-protein that inhibits adenylate cyclase. The AT1R is expressed in the heart, blood vessels, kidney, adrenal cortex, lung and brain. The AT1R protein is encoded by the AGTR1 gene located on chromosome 3q24. The AT2 receptor is also a GPCR and is coupled to activation of Gi-proteins. Expression of the AT2R is limited, in the adult, to the brain (predominantly the cerebellum), adrenal gland, and myometrium. Within the brain the primary AT2R ligand is angiotensin III.
Due primarily to the development of a dry hacking cough with the use of ACE inhibitors, drugs that block the activity of the AT1R were developed for the treatment of hypertension. This class of drug is called the angiotensin receptor blocker (ARB) class. All of the ARB drugs are AT1R antagonists and thus, exert their anti-hypertensive effects at the level of the receptor itself. All drugs in the ARB class contain the suffix "–sartan". In addition to their use in the treatment of hypertension the ARBs are used to treat diabetic nephropathy and congestive heart failure.back to the top
Parathyroid hormone (PTH) is synthesized and secreted by chief cells of the parathyroid glands in response to systemic Ca2+ levels. There are four parathyroid glands that lie adjacent to the thyroid gland and consist of two superior glands and two inferior glands. The PTH gene is located on chromosome 11p15.3–p15.1 and consists of 3 exons encoding a 115 amino acid preproprotein. In the PTH mRNA exon 1 is untranslated, exon 2 encodes a 25-amino acid signal peptide and part of the prohormone, and exon 3 encodes the remaining part of the prohormone (6 amino acids) and the whole biologically active 84 amino acid (molecular weight of 9300 Daltons) PTH protein. As PTH is synthesized it is processed through the ER and Golgi apparatus where first the signal peptide is removed and then the propeptide with the active PTH molecule stored in dense neuroendocrine-type granules. There exists a related protein identified as PTH-related protein (PTHrP). PTHrP was identified originally as a protein causing severe hypercalcemia in patients with pheochromocytoma (PCC) which is a rare malignancy of the chromaffin cells of the adrenal medulla. The normal functions of PTHrP include roles in fetal bone development where it suppresses the maturation of chondrocytes so that the onset of hypertrophic differentiation during endochondral bone growth is delayed. In addition PTHrP exhibits antiproliferative effects in adults by regulating epidermal and hair follicle cell growth as well as inhibiting angiogenesis.
The Ca2+ receptor of the parathyroid gland responds to Ca2+ by increasing intracellular levels of PKC, Ca2+ and IP3; this stage is followed, after a period of protein synthesis, by PTH secretion. The synthesis and secretion of PTH from chief cells is constitutive, but Ca2+ regulates the level of PTH in chief cells (and thus its secretion) by increasing the rate of PTH proteolysis when plasma Ca2+ levels rise and by decreasing the proteolysis of PTH when Ca2+ levels fall. The role of PTH is to regulate Ca2+ concentration in extracellular fluids. The feedback loop that regulates PTH secretion therefore involves the parathyroid, Ca2+, and the target tissues described below.
PTH acts by binding to cAMP– and PLCβ–activating plasma membrane receptors, initiating a cascade of reactions that culminates in the biological response. There are two receptors that recognize PTH identified as the PTH-1 and PTH-2 receptors (PTH1R and PTH2R). The PTH1R gene is located on chromosome 3p22–p21.1 spanning 32kbp and composed of 15 exons that encode a 585 amino acid protein. The PTH2R gene is located on chromosome 2q33. These receptors are coupled to Gs-proteins that activate adenylate cyclase resulting in increased cAMP and consequent activation of PKA, as well as Gq-proteins that activate PLCβ resulting in hydrolysis of membrane PIP2 releasing IP3 and DAG. The IP3 stimulates release of intracellular Ca2+ stores and DAG activates PKC. The PTH-1 receptor is activated by both PTH and PTHrP, whereas, the PTH-2 receptor is activated only by PTH. Both receptors are related to a small sub-family of peptide hormone receptors that includes the receptors for ACTH, calcitonin, vasoactive intestinal peptide (VIP), and secretin. The PTH-1 receptor is found predominantly in bone and kidney. The body response to PTH is complex but is aimed in all tissues at increasing Ca2+ levels in extracellular fluids. PTH induces the dissolution of bone by stimulating osteoclast activity, which leads to elevated plasma Ca2+ and phosphate. In the kidney, PTH reduces renal Ca2+ clearance by stimulating its reabsorption; at the same time, PTH reduces the reabsorption of phosphate and thereby increases its clearance. Finally, PTH acts on the liver, kidney, and intestine to stimulate the production of the steroid hormone 1,25-dihydroxycholecalciferol (calcitriol), which is responsible for Ca2+ absorption in the intestine.
Although the primary function of PTH is to respond to reduced circulating Ca2+ levels and a portion of its action results in resorption of bone Ca2+, the use of recombinant PTH has proven beneficial in the treatment of osteoporosis. PTH increases bone turnover (resorption) but it also increases the formation of new bone and the latter effect on bone is more pronounced than resorption. Intermittent infusion of recombinant PTH (Forteo®) results in new bone formation and has shown efficacy in the treatment of the bone loss associated with osteoporosis. This PTH-induced phenomenon occurs as a result of the laying down of protein matrix and mineralization that occurs not only in the previous existing matrix, but in the new matrix that is formed. Patients receiving Forteo demonstrate an increase in bone density as measured at the osteoporosis center(s) as well as a decrease in fractures compared to other forms of treatment. Whereas, continuous elevation of PTH levels, as occurs in humans due to abnormal secretion from the parathyroid glands results in loss of bone mass leading to osteoporosis, intermittent elevation of PTH that occurs with the daily injections of Forteo has the opposite effect of building bone.back to the top
Calcitonin is a 32-amino acid peptide secreted by C cells of the thyroid gland. Calcitonin is a hypocalcemic peptide that exerts its effects in numerous species by antagonizing the effects of PTH. In humans, however, the role of calcitonin in calcium homeostasis is of limited physiological significance. The circulating levels of calcitonin are low and extreme variations in these levels have not been associated with disruptions in calcium or phosphate homeostasis in humans. There are two human calcitonin genes identified as α and β. The α gene (symbol: CALCA) is located on chromosome 11p15.2–p15.1 spanning 6.5kbp and composed of 6 exons. The β gene (symbol: CALCB) is located on the same chromosome location as the CALCA gene. Transcription of the CALCA gene yields two different mRNAs as a result of alternative splicing. The two mRNAs are translated into two distinctly different proteins with distinct biological activities. These two proteins are calcitonin and the neuropeptide calcitonin gene-related protein (CGRP, also identified as α-CGRP). Exon 1 of the CALCA gene is a non-coding exon and exons 2–4 encode calcitonin. The CGRP mRNA is composed of exons 1–3, 5 and 6. The CALCB gene encodes β-CGRP (also identified as CGRP-2) mRNA which is translated into CGRP in the central nervous system. The CGRP produced from the CALCB gene exhibits cardiovascular effects, neurotransmitter functions, and may serve a role in early development.
CGRP has recently been shown to play a role in the metabolic changes associated with aging. These effects are exerted via an interactive pathway involving pain receptors of the transient receptor potential cation channel subfamily V member 1 (TRPV1) pain receptors. TRPV1 expressing neurons form a dense network innervating the pancreas. Stimulation of these receptor induces the release of substance P and CGRP. Within the pancreas, substance P induces neurogenic inflammation while CGRP antagonizes insulin release. When the TRPV1 gene is knocked out in mice there is a significant decrease in CGRP release from neurons in the pancreas resulting in insulin secretion and the promotion of metabolic health. These TRPV1 knock-out mice are long-lived and display the metabolic profiles of more youthful mice even when they are older. These results suggest that inhibition of specific pain response pathways and/or antagonism of CGRP signaling within the pancreas could hold promise in the treatment of age related metabolic disturbances.
In non-human species, calcitonin exerts its hypocalcemic effects primarily through inhibition of osteoclast-mediated bone resorption. Calcitonin has been shown to reduce the synthesis of osteopontin (OPN, also referred to as secreted phosphoprotein 1, SPP1), a protein made by osteoclasts and responsible for attaching osteoclasts to bone. Secondarily, calcitonin affects serum Ca2+ levels by the stimulation of renal Ca2+ clearance. These effects of calcitonin are the result of the interaction of the hormone with a specific receptor (identified as the CTR). The CTR is closely related to the PTH and the secretin receptors which together, as described above for PTH, form a distinct subfamily of GPCRs. The CTR gene (symbol: CALCR) is located on chromosome 7q21.3.
In humans the major benefits of calcitonin are its use in the treatment of osteoporosis and to suppress bone resorption in Paget disease. Paget disease (osteitis deformans) is a disorder of bone remodeling that results in accelerated rates of bone turnover and disruption of normal bone architecture. The naturally occurring calcitonins vary in amino acid sequence between species. The salmon calcitonin is 10–100 times more potent than mammalian species in lowering serum calcium levels and because of this activity it is used therapeutically such as in the treatment of Paget disease. The other medically significant fact related to calcitonin is its use as a biomarker for sporadic and inherited forms of medullary cancers.
In addition to calcitonin and CGRP, the calcitonin family of peptides includes amylin, adrenomedulin (AM) and adrenomedulin 2 (AM2, also known as intermedin). These peptides all interact with receptor complexes that contain the calcitonin receptor at their cores. The two G protein-coupled receptors (GPCRs) which are receptors for these peptides are the calcitonin receptor (CTR; gene symbol: CALCR) and the calcitonin receptor-like receptor (CLR, also known as CRLR). These belong to the sub-family of GPCRs known as the secretin-like or class B family of GPCRs (see the Signal Transduction page for more information on GPCR classes). CTR and CLR can form complexes with members of the membrane protein family called the receptor activity-modifying proteins (RAMPs), which consists of RAMP1, RAMP2 and RAMP3 in humans. RAMPs are type I transmembrane proteins composed of a large N-terminal extracellular domain, a single α-helical transmembrane domain and a short intracellular domain. These proteins regulate receptor pharmacology, receptor signaling, and receptor trafficking. RAMP association with CTR or with CLR generates multiple distinct receptor subtypes with different specificities for the calcitonin peptide family. CLR together with RAMP1 forms the CGRP receptor. In contrast, two AM receptors are formed by CLR and RAMP2 or RAMP3, respectively. Interaction of each of the three RAMPs with CTR form the amylin receptors described below.back to the top
The primary function of the pancreatic hormones is the regulation of whole-body energy metabolism, principally by regulating the concentration and activity of numerous enzymes involved in catabolism and anabolism of the major cell energy supplies.
The earliest of these hormones recognized was insulin, whose major function is to counter the concerted action of a number of hyperglycemia-generating hormones and to maintain low blood glucose levels. Because there are numerous hyperglycemic hormones, untreated disorders associated with insulin generally lead to severe hyperglycemia and shortened life span. Insulin is a member of a family of structurally and functionally similar molecules that include the insulin-like growth factors (IGF-1 and IGF-2), and relaxin. The tertiary structure of all 4 molecules is similar, and all have growth-promoting activities, but the dominant role of insulin is metabolic while the dominant roles of the IGFs and relaxin are in the regulation of cell growth and differentiation. For an extended discussion of the actions of insulin see the Insulin Action page.
Insulin is synthesized as a preprohormone in the β-cells of the islets of Langerhans. Its signal peptide is removed in the cisternae of the endoplasmic reticulum and it is packaged into secretory vesicles in the Golgi, folded to its native structure, and locked in this conformation by the formation of 2 disulfide bonds. Specific protease activity cleaves the center third of the molecule, which dissociates as C peptide, leaving the amino terminal B peptide disulfide bonded to the carboxy terminal A peptide.
Insulin secretion from β-cells is principally regulated by plasma glucose levels and is referred to as glucose-stimulated insulin secretion, GSIS. The increased uptake of glucose by pancreatic β-cells leads to a concomitant increase in metabolism. The increase in metabolism leads to an elevation in the ATP/ADP ratio. This in turn leads to an inhibition of an ATP-sensitive K+ channel. The net result is a depolarization of the cell leading to Ca2+ influx and insulin secretion.
Chronic increases in numerous other hormones (including GH, hPL, estrogens, and progestins), up-regulate insulin secretion, probably by increasing the preproinsulin mRNA and enzymes involved in processing the increased preprohormone. In contrast, epinephrine diminishes insulin secretion by a cAMP-coupled regulatory path. In addition, epinephrine counters the effect of insulin in liver and peripheral tissue, where it binds to β-adrenergic receptors, induces adenylate cycles activity, increases cAMP, and activates PKA. The latter events induce glycogenolysis and gluconeogenesis, both of which are hyperglycemic and which thus counter insulin's effect on blood glucose levels.
Insulin secreted by the pancreas is directly infused via the portal vein to the liver, where it exerts profound metabolic effects. In most other tissues insulin increases the number of plasma membrane glucose transporters, but in liver glucose uptake is dramatically increased because of increased activity of the enzymes glucokinase, phosphofructokinase-1 (PFK-1), and pyruvate kinase (PK), the key regulatory enzymes of glycolysis. The latter effects are induced by insulin-dependent activation of phosphodiesterase, with decreased PKA activity and diminished phosphorylation of the regulatory glycolytic enzymes. In addition, phosphatases specific for the phosphorylated forms of the glycolytic enzymes increase in activity under the influence of insulin. All these events lead to conversion of the glycolytic enzymes to their active forms and consequently a significant increase in glycolysis. In addition, glucose-6-phosphatase activity is down-regulated. The net effect is an increase in the content of hepatocyte glucose and its phosphorylated derivatives, with diminished blood glucose.
In addition to the latter events, diminished cAMP and elevated phosphatase activity combine to convert glycogen phosphorylase to its inactive form and glycogen synthase to its active form, with the result that not only is glucose funneled to glycolytic products, but glycogen content is increased as well.
Insulin generates its intracellular effects by binding to a plasma membrane receptor, which is the same in all cells. The receptor is a disulfide-bonded glycoprotein. One function of insulin (aside from its role in signal transduction) is to increase glucose transport in extrahepatic tissue is by increasing the number of glucose transport molecules in the plasma membrane. Glucose transporters are in a continuous state of turnover. Increases in the plasma membrane content of transporters stem from an increase in the rate of recruitment of new transporters into the plasma membrane, deriving from a special pool of preformed transporters localized in the cytoplasm.
In addition to its role in regulating glucose metabolism, insulin stimulates lipogenesis, diminishes lipolysis, and increases amino acid transport into cells. Insulin also modulates transcription, altering the cell content of numerous mRNAs. It stimulates growth, DNA synthesis, and cell replication, effects that it holds in common with the IGFs and relaxin.
Glucagon is a 29-amino acid hormone synthesized by the α-cells of the islets of Langerhans of the endocrine pancreas. The glucagon peptide is derived by proteolytic processing from the very much larger proglucagon protein. The organization and differential processing of the proglucagon protein is described in greater detail in the Gut-Brain Interrelationships page. Like insulin, glucagon lacks a plasma carrier protein, and like insulin its circulating half life is also about 5 minutes. As a consequence of the latter trait, the principal effect of glucagon is on the liver, which is the first tissue perfused by blood containing pancreatic secretions.
The role of glucagon is well established. It binds to a plasma membrane G-protein coupled receptor (GPCR), that via activation of a Gs-type G-protein, leads to activation of adenylate cyclase. The resultant increases in cAMP lead to activation of the kinase, PKA, which in turn phosphorylates numerous substrates resulting in a reversal of most of the effects described above that insulin has on liver. The increases in PKA activity also lead to a marked elevation of circulating glucose, with the glucose being derived from liver gluconeogenesis and liver glycogenolysis. Activation of the glucagon receptor in hepatocytes has also been shown to be coupled to activation the phospholipase C-β (PLCβ) and inositol trisphosphate (IP3) pathway involved in the mobilization of intracellular Ca2+. The glucagon receptor is derived from the GCGR gene which is located on chromosome 17q25 and is composed of 15 exons that encode a protein of 477 amino acids.
Glucagon also binds to its receptor in the kidney and, to a lesser extent, in adipose tissue, heart, endocrine pancreas, adrenal glands, spleen, and cerebral cortex. The binding of glucagon to its receptors in adipose tissue results in increased activation of hormone-sensitive lipase (HSL). The actions of HSL lead to increased release of fatty acids stored in the triglycerides in adipose tissue. The released fatty acids enter the circulation, are bound by albumin and transported to various tissues for oxidation. In the liver the oxidation of fatty acids is necessary to provide the energy needed for gluconeogenesis which is activated in liver in response to glucagon. Within the endocrine pancreas, the glucagon receptor is found on the β-cells that secrete insulin. The effect of glucagon on these cells is to stimulate insulin release so that there results a fine regulatory control over the overall level of circulating glucose.back to the top
Somatostatin is secreted by enteroendocrine D cells of the stomach and duodenum, δ-cells of the pancreas and is also secreted by the hypothalamus. There are two forms of somatostatin identified as SS-28 and SS-14. Both forms have identical C-terminal sequences. The SS-28 form is the predominant form within the gut. In neural tissue somatostatin inhibits GH secretion and, thus, has systemic effects. In the pancreas, somatostatin acts as a paracrine inhibitor of other pancreatic hormones and, thus, also has systemic effects. It has been speculated that somatostatin secretion responds principally to blood glucose levels, increasing as blood glucose levels rise leading to down-regulation of glucagon secretion. In the gut, somatostatin is involved in the inhibition of gastric acid secretion. Somatostatin binds to a GPCR called the somatostatin receptor 1 (encoded by the SSTR1 gene) that is coupled to a Gi-type G-protein that inhibits adenylate cyclase. The effect of somatostatin binding to SSTR1 is an antagonism of the gastric acid secreting effects of histamine. Somatostatin can also interfere with the gastric effects of histamine by blocking histamine release from enterochromaffin-like cells (ECL) in the gastric mucosa.back to the top
Amylin is a 37 amino acid peptide that is secreted from β-cells of the pancreas simultaneously with insulin in response to nutrient intake. Amylin has also been called islet amyloid polypeptide (IAPP). Amylin was originally identified as a major component of diabetes-associated islet amyloid deposits, hence its original name IAPP. The structurally active form of amylin exists with an intrachain disulfide bond and an amidated C-terminus. When assayed by immunohistochemical means approximately 60% of amylin peptide present in the plasma is glycosylated. The functional significance of the glycosylation is currently unknown and when assayed in vitro the glycosylated peptide is biologically inactive. The primary actions attributable to amylin secretion are reduction in the rate of gastric emptying, suppression of food intake, and suppression of post-meal glucagon secretion. Collectively these three actions compliment the plasma glucose concentration regulating actions of insulin. The anorexigenic actions of amylin are most likely mediated within the CNS via neurons in the area postrema as evidenced by the fact that peripheral administration of amylin to animals results in neuronal activation in this region of the brain. The plasma half-life of amylin is quite short being less than 15 minutes. The clearance of amylin from the plasma occurs via the kidneys both through renal excretion and renal peptidases associated with the vascular supply. A stable analog of amylin called pramlintide (Symlin ®) is used as an adjunct to insulin treatment for type 1 and type 2 diabetes. Patients who use pramlintide show a modest degree of weight loss. Current trials are being undertaken to establish the efficacy of pramlintide in the treatment of obesity in patients without diabetes.
Amylin exerts its effect via interaction with GPCR complexes of the secretin-like receptor family (GPCR class B receptors). There are three distinct receptor complexes that bind amylin. These complexes all contain the calcitonin receptor (CTR) as a core protein and either one of three receptor activity-modifying proteins (RAMPs), RAMP1, RAMP2 or RAMP3. The specific amylin receptors result from the dimerization of various splice variants of the calcitonin receptor (CTRa or CTRb) with either RAMP1, RAMP2 and RAMP3. These receptors are commonly referred to as AMY1, AMY2 and AMY3 with either an a or b in the subscript designating which CTR splice variant of the calcitonin receptor is in the complex. Amylin receptors expressed in the nucleus accumbens, the dorsal raphe and the area postrema in the hind brain. Studies in rats have demonstrated that AMY2a and AMY3a are the amylin receptor subtypes localized to the area postrema which indicates that the satiety inducing effects of amylin are the result of activation of these two receptor subtypes. Within the area postrema, the key second messenger system associated with the amylin receptors appears to be cGMP. The calcitonin receptor-like receptor (CRLR) and both RAMP1 and RAMP2 are expressed in the subfornical organ and are likely responsible for the involvement of amylin in drinking behaviors. RAMP1 and RAMP2 but not RAMP3 have been shown to be expressed in the rat nucleus accumbens suggesting that the amylin receptor in the nucleus accumbens is either AMY1 or AMY2. The precise role of these amylin receptors in the nucleus accumbens haven not been well-established but it has been proposed that they may link food intake behavior and motor activity to amylin function. Peripheral injection of amylin demonstrates that the peptide crosses the blood-brain barrier resulting in access to a number of brain regions such as the cerebellum, midbrain, frontal cortex, parietal cortex, and occipital cortex.back to the top